#United States #San Diego #cancer detection #Helio Genomics #Hepatocellular Carcinoma

Helio Genomics Presents Groundbreaking Research at Digestive Disease Week

Helio Genomics, a leading AI-powered healthcare company, has announced it will be presenting three groundbreaking abstracts at the upcoming 2025 Digestive Disease Week, taking place from May 4 to May 6 at the San Diego Convention Center. This year's conference promises to be an exciting event for specialists in the fields of gastroenterology and hepatology, especially with the introduction of significant advancements in cancer detection methodologies.

Major Highlights

Among the highlights is a longitudinal study that juxtaposes the efficiency of their innovative multi-analyte blood test, known as HelioLiver, against traditional ultrasound procedures specifically designed for detecting hepatocellular carcinoma (HCC) in patients with existing cirrhosis. This study marks a pivotal moment as it serves as the first simulation aimed at understanding the real-world implications of these testing methodologies in a clinical context.

Poster Presentations

The details of the presentations are as follows:
1. Poster #1: “Simulation of Longitudinal Ultrasound versus a Multi-Analyte Blood-Based Test for Detecting Hepatocellular Carcinoma in Patients with Cirrhosis”
- Presented by: Dr. Amit Singal, MD, MS, FAASLD, Professor of Medicine at UT Southwestern Medical Center.
- Focus: This study will delve into the comparative analysis of HelioLiver against ultrasound techniques, which have long been the industry standard for HCC detection.

2. Poster #2: “Cell-Free DNA Methylation Biomarkers for Evaluating Prognosis and Treatment Response in Patients with Hepatocellular Carcinoma”
- Presented by: Shivani Mahajan, Ph.D., Head of Computational Science at Helio Genomics.
- Focus: Here, the discussion will center on how cell-free DNA methylation patterns can provide insights into prognosis and assist in tailoring treatment responses for HCC patients.

3. Poster #3: “CLiMB: A Prospective, Blinded, Multicenter U.S. Based Study Evaluating a Multi-Analyte Blood-Based Test for Detecting Hepatocellular Carcinoma in Patients with Liver Cirrhosis”
- Presented by: Dr. Richard Van Etten, MD, PhD, Director of the Chao Family Comprehensive Cancer Center at UCI, and Chief Medical Advisor at Helio Genomics.
- Focus: This presentation will encompass the results and insights drawn from a comprehensive study that evaluates the efficacy of HelioLiver within a diverse patient demographic dealing with liver cirrhosis.

These presentations, scheduled for May 6, 2025, from 12:30 to 1:30 PM PT, signify more than just academic discussions; they reflect the commitment of Helio Genomics towards revolutionizing cancer detection mechanisms and enhancing patient outcomes through advanced testing technologies. All the poster presentations will later be accessible in the “Past Events” section on the Helio Genomics website for those unable to attend the conference.

About Helio Genomics

Founded with a vision to transform cancer diagnostics, Helio Genomics specializes in developing advanced testing technologies powered by artificial intelligence. Their leading product, HelioLiver, is a multi-analyte blood test that measures cfDNA methylation patterns, serum protein markers, and demographic data to facilitate early and accurate detection of hepatocellular carcinoma.

To learn more about their groundbreaking work and access important investor information, visit their official websites at Helio Genomics or LinkedIn. This approach aligns with their core mission of utilizing technology to improve healthcare outcomes.

With its active participation at this key conference, Helio Genomics is poised to emphasize its role as a pioneering entity in the field of cancer diagnostics and research.